Business, Health Care

LabCorp and HealthEC launch transformative oncology care module

New Software Tool Designed to Help Oncologists Improve Patient Outcomes and Achieve Cost-Saving Goals Available Exclusively through LabCorp and Powered by HealthEC® BURLINGTON, N.C. & EDISON, N.J.–(BUSINESS WIRE)–LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health

Business, Health Care

Opdivo (nivolumab) plus chemotherapy show statistically significant improvement in pathologic complete response as neoadjuvant treatment of resectable non-small cell lung cancer in phase 3 CheckMate-816 trial

[contact-form][contact-field label=”Name” type=”name” required=”true” /][contact-field label=”Email” type=”email” required=”true” /][contact-field label=”Website” type=”url” /][contact-field label=”Message” type=”textarea” /][/contact-form] CheckMate –816 met a primary endpoint of improved pathologic complete response in patients who received Opdivo plus chemotherapy before surgery Positive results mark the first time an